Irritable Bowel Syndrome Drugs Market Size & Share, by Type {IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), Mixed IBS (IBS-M)}; End-user (Drug Stores & Retail, Hospital, Online Pharmacies); Product (Xifaxan, Linzess, Amitiza, Viberzi) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 3040
  • Published Date: Feb 10, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023-2035

Irritable Bowel Syndrome Drugs Market size is poised to cross USD 5 Billion by the end of 2035, growing at a CAGR of 14% during the forecast period, i.e., 2023-2035. In the year 2022, the industry size of irritable bowel syndrome drugs was over USD 2 Billion. The growth of the market can be attributed to the increasing number of elderly people who are prone to different types of gastrointestinal diseases. Further, the growing prevalence of gastrointestinal diseases amongst other population group, an increase in the consumption of unhealthy foods, and rising stress levels among people across the globe are also expected to add to the market growth. The estimated prevalence of irritable bowel syndrome in the United States is between 11% and 14% and this share is predicted to increase further in the years to come.

In addition to these, factors that are believed to fuel the market growth of irritable bowel syndrome drugs include the rise in over-the-counter drug availability, soaring investments, and collaboration between major key players to discover effective treatments for IBS. For instance, on June 9, 2022, the biopharmaceutical company Ferring B.V. announced a strategic partnership with the innovation-focused global biopharma company I-MAB Biopharma Co., Ltd. to advance the development of olamkicept, a selective interleukin-6 (IL-6) trans-signaling inhibitor for inflammatory bowel disease (IBD) and associated inflammatory conditions. Additionally, the growing number of awareness campaigns on the management of irritable bowel syndrome is predicted to present the potential for market expansion over the projected period.


IBS-drug-mnarket
Get more information on this report: Request Free Sample PDF

Irritable Bowel Syndrome Drugs Sector: Growth Drivers and Challenges

Growth Drivers

  • Growing Prevalence of Diarrhea in Children – On account of the increasing prevalence of gastrointestinal disorders in children, including diarrhea, constipation, and bowel incontinence, the market is expected to expand more in the upcoming years. Diarrhea is listed as the second most typical cause of death in children under the age of five by the World Health Organization. Each year, diarrhea kills about 500 000 children under the age of five. Around 2 billion children worldwide have diarrheal sickness every year.
  • Rising Geriatric Population – Elderly population is more prone to bowel incontinence and the rising number of elderly populations across the globe is estimated to drive market growth. The percentage of individuals over 60 in the world will nearly double from 12 to 22% between 2015 and 2050. In 2020, there were more people over the age of 60 than children under five and by 2050, it is predicted that 80% of the world's old people will live in low- and middle-income countries.
  • Increasing Health Spending – According to the most recent expenditure data, global health spending has grown over the past 20 years, doubling in real terms to reach USD 8.5 trillion in 2019 and 9.8% of GDP, up from 8.5 percent in 2000. It is predicted that this boom would continue over the forecast period.
  • Growing Incidences of Spinal Cord Injuries – It is expected that patients with chronic illnesses and disabilities, including spinal cord injuries, experience bowel incontinence more severely, which is anticipated to drive the market growth. It was discovered that between 300,000 and 500,000 people worldwide experience spinal cord injuries every year.
  • Rising Cases of Hemorrhoids – Hemorrhoids can also be referred to as piles. Inflamed veins in the lower rectum and anus are hemorrhoids. Bowel incontinence can result from this swelling, thereby raising the need for hemorrhoids drugs, which is anticipated to drive the market growth. At least 50% of Americans over the age of 50 who have hemorrhoids experience obvious symptoms.

Challenges

  • Side effects of IBS drugs - The increasing concern amongst individuals for the side effects associated with the consumption of IBS drugs is one of the major factors predicted to slow down the market growth. For instance, pancreatitis, a serious and more common pancreatic inflammation, can arise from the dual mu-opioid nicotinic receptor eluxadoline, which is employed to address digestive problems with incontinence in some people.
  • Low awareness among people in low and middle-income countries for these drugs
  • Lack of medical reimbursement policies for treatment of IBS

Irritable Bowel Syndrome Drugs Market: Key Insights

Base Year

2022

Forecast Year

2023-2035

CAGR

14%

Base Year Market Size (2022)

USD 2 Billion

Forecast Year Market Size (2035)

USD 5 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Irritable Bowel Syndrome Drugs Segmentation

Type {IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), Mixed IBS (IBS-M)}

The global irritable bowel syndrome drugs market is segmented and analyzed for demand and supply by type into IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and mixed IBS (IBS-M). Out of these, the IBS with diarrhea (IBS-D) segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the increasing prevalence of diarrhea among all age groups and the rising adoption of unhealthy lifestyles including the consumption of fast food and alcohol. For instance, diarrheal illnesses are believed to be responsible for 300 annual pediatric fatalities and 167,000 hospitalizations in the US.

Our in-depth analysis of the global irritable bowel syndrome drugs market includes the following segments:

      By Type

  • IBS with Diarrhea (IBS-D)
  • IBS with Constipation (IBS-C)
  • Mixed IBS (IBS-M)

      By Product

  • Xifaxan
  • Linzess
  • Amitiza
  • Viberzi
  • Others

      By End User

  • Drug Stores & Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Irritable Bowel Syndrome Drugs Industry - Regional Synopsis

North America Market Forecast

The North American irritable bowel syndrome drugs market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035. The growth of the market can be attributed to the increasing frequency of fecal incontinence and the availability of efficient treatment options in the region. For instance, 50 to 70 patients out of every 100 nursing home residents and 18 to 33 patients out of every 100 hospitalized patients, respectively, suffer from fecal incontinence. Fecal incontinence affects 7 to 15 persons out of every 100 who are not patients or residents of nursing homes or hospitals. In addition, the region's supportive health policies and expanding healthcare industry are anticipated to boost the market expansion during the course of the anticipated period.

Research Nester
IBS-drug-mnarket-size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Irritable Bowel Syndrome Drugs Landscape

top-features-companies
    • Abbott Services
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Ardelyx, Inc.
    • Astellas Pharma Inc.
    • AstraZeneca
    • GlaxoSmithKline Plc
    • Johnson & Johnson Services, Inc.
    • Novartis AG
    • Ironwood Pharmaceuticals, Inc.
    • Synergy Pharma Consultancy Private Limited
    • Synthetic Biologics, Inc 

In the News

  • IBSRELA the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, has been made available by the biopharmaceutical company Ardelyx. The first Ardelyx product to receive approval from the US Food and Drug Administration is IBSRELA.

  •  Indegene a provider of technology-driven healthcare solutions, and metaMe Health, a maker of Regulora and a Prescription Digital Therapeutics (PDT) business, teamed up to offer Regulora as a remedy for irritable bowel syndrome-related stomach pain (IBS).

Author Credits:  Radhika Pawar


  • Report ID: 3040
  • Published Date: Feb 10, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing incidences of irritable bowel syndrome and growing availability of over the counter drugs are estimated to boost market growth.

The market is anticipated to attain a CAGR of 14% over the forecast period, i.e., 2023-2035.

Lack of awareness regarding IBS treatment and the side effects of IBS drugs are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Ardelyx, Inc., Astellas Pharma Inc., AstraZeneca, GlaxoSmithKline Plc, and Johnson & Johnson Services, Inc.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by type, product, end user, and by region.

The IBS with diarrhea (IBS-D) segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Irritable Bowel Syndrome Drugs Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying